SCA
OREX

SAC Capital Advisors’s Orexigen Therapeutics, Inc. OREX Stock Holding History

SAC Capital Advisors’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-20,000
Closed -$1.13M – 2205
2013
Q4 		$1.13M Buy
+20,000
New +$1.12M 0.01% 873

Other funds holding OREX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SAC Capital Advisors's OREX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2014, closing a stake of 67,680 shares — an estimated $4.4M sold.

SAC Capital Advisors first reported a position in OREX in Q2 2013 and held it in 4 quarters. The position peaked at $22.5M in Q4 2013. 129 funds tracked by Wall St. Rank hold OREX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 67,680 Orexigen Therapeutics, Inc. shares in Q2 2014, an estimated $4.4M.
  • SAC Capital Advisors first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 4 quarters.
  • SAC Capital Advisors's Orexigen Therapeutics, Inc. position peaked at $22.5M in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.